February 7, 2020

Traditional herbal medicinal products and nutritional supplements: criteria of distinction

With judgment No. 14408 of December 13, 2019, the Administrative Court of the Lazio Region provided clarification on the distinction between traditional herbal medicinal products and nutritional supplements.

The case concerned a challenge to the lawfulness of the decree issued by the Ministry of Health on August 10, 2018 (on botanicals), in which the Ministry of Health added the herbal substance Pelargonium sidoides to the list of substances authorized to be used in nutritional supplements. Specifically, the claimant, who holds an authorization for a traditional herbal medicinal products based on such substance, argued that Pelargonium sidoides should be marketed exclusively as medicine and not as a supplement.

With its ruling, the court clarified the difference between traditional herbal medicinal products and nutritional supplements: that distinction is not based on scientifically recognized therapeutic efficacy, since neither group has been recognized  such therapeutic efficacy. Rather, the distinction is based on a guarantee of safe use.

Indeed, while registration of traditional herbal medicinal products is based on their use in Europe for at least fifteen years, in accordance with Articles 21 and 23 of Legislative Decree No. 219 of April 24, 2006, as to nutritional supplements, it is necessary to provide a guarantee that they are safe to use in accordance with Legislative Decree No. 169 of May 21, 2004.

Therefore, the Ministry of Health may add substances to the list of herbal substances allowed in the preparation of nutritional supplements when new scientific evidence and deeper investigation permit to reach the prove of their safe use.

< Back to blog
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the life sciences and healthcare industry.
...
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and venture capital transactions.

Close
September 21, 2022
Payback for medical devices: Decree quantifying the exceeding of the expenditure ceiling for medical devices at national and regional level for the years 2015, 2016, 2017 and 2018 published ...
September 1, 2022
The 2021 annual law for market and competition addressing, as to the healthcare sector, reimbursement of drugs, intermediate distribution, patent linkage and institutional accreditation of p...
July 19, 2022
Guidelines for the implementation of the Electronic Health Record (EHR) to ensure dissemination, uniformity and accessibility of the EHR at national level now published in the Official Gazet...
June 6, 2022
The National Coordination Centre for Ethics Committees published new draft agreements for conducting clinical trials on drugs and medical devices
April 27, 2022
EU Medical Device Coordination Group (MDCG) approves “Guidance” on the borderline between medical devices and medicinal products in order to support the uniform application of Regulation...
Search by...
Search
Follow us on
Follow us on